Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: A phase 2b study

Sleep

Volumn 39, Issue 7, 2016, Pages 1379-1387

  Ruoff, Chad ^a   Swick , Todd J ^b   Doekel, Robert ^c   Emsellem, Helene A ^d   Feldman, Neil T ^e   Rosenberg, Russell ^f   Bream, Gary ^g   Khayrallah, Moise A ^g   Lu , Yuan ^h   Black, Jed ^a,h  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Sleep Disorders Center of Alabama   (United States)

^d Center for Sleep and Wake Disorders   (United States)

^e Palms of Pasadena Hospital   (United States)

^f Neuro Trials Research   (United States)

^g Aerial BioPharma LLC   (United States)

^h JAZZ PHARMACEUTICALS   (United States)

Author keywords

Excessive sleepiness; JZP 110; Narcolepsy; Wakefulness

Indexed keywords

2 AMINO 3 PHENYLPROPYLCARBAMATE HYDROCHLORIDE; DOPAMINE RECEPTOR BLOCKING AGENT; NORADRENALIN UPTAKE INHIBITOR; PHENYLALANINE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; WAKEFULNESS PROMOTING AGENT; (R)-2-AMINO-3-PHENYLPROPYLCARBAMATE HYDROCHLORIDE; CARBAMIC ACID DERIVATIVE; PHENYLALANINE;

ACUTE CHOLECYSTITIS; ADULT; AGED; AGITATION; ANXIETY DISORDER; ARTICLE; BRUXISM; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CONVERSION DISORDER; DEATH; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CHRONOTHERAPY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EPWORTH SLEEPINESS SCALE; EUPHORIA; EVALUATION STUDY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; IRRITABILITY; LOW DRUG DOSE; MAINTENANCE OF WAKEFULNESS TEST; MALE; MEDICATION COMPLIANCE; MORNING DOSAGE; MULTICENTER STUDY; NARCOLEPSY; NAUSEA; PARALLEL DESIGN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP; SLEEP DISORDER ASSESSMENT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TACHYPHRENIA; TENSION HEADACHE; THOUGHT DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; WAKEFULNESS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; SLEEP STAGE;

ADULT; AGED; CARBAMATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; PHENYLALANINE; SLEEP STAGES; TREATMENT OUTCOME; WAKEFULNESS; WAKEFULNESS-PROMOTING AGENTS;

EID: 84978808821     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.5968     Document Type: Article

References (33)

1. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association, 2013.
3. Dodel R, Peter H, Spottke A, et al. Health-related quality of life in patients with narcolepsy. Sleep Med 2007;8:733-41.
4. Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med 2012;13:1086-93.
5. Black J, Reaven NL, Funk S, et al. The Burden of Narcolepsy Disease (BOND) Study: Healthcare Utilization and Cost Findings. Sleep Med 2014;15:522-9.
6. Sangal RB, Thomas L, Mitler MM. Maintenance of wakefulness test and multiple sleep latency test. Measurement of different abilities in patients with sleep disorders. Chest 1992;101:898-902.
7. Sangal RB, Mitler MM, Sangal JM. Subjective sleepiness ratings (Epworth sleepiness scale) do not reflect the same parameter of sleepiness as objective sleepiness (maintenance of wakefulness test) in patients with narcolepsy. Clin Neurophysiol 1999;110:2131-5.
8. Fronczek R, Middelkoop HA, van Dijk JG, Lammers GJ. Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). Sleep 2006;29:187-91.
9. Sadeghniiat-Haghighi K, Moller HJ, Saraei M, Aminian O, Khajeh-Mehrizi A. The Epworth Sleepiness Scale for screening of the drowsy driving: comparison with the maintenance of wakefulness test in an Iranian sample of commercial drivers. Acta Med Iran 2014;52:125-9.
10. Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006;13:1035-48.
11. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007;30:1705-11.
12. Keam S, Walker MC. Therapies for narcolepsy with or without cataplexy: evidence-based review. Curr Opin Neurol 2007;20:699-703.
13. Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic managment of narcolepsy. Sleep Med 2015;16:9-18.
14. Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol 2013;4:139.
15. Rothman RB, Baumann MH, Dersch CM, et al. Amphetaminetype central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
16. Hasan S, Pradervand S, Ahnaou A, Drinkenburg W, Tafti M, Franken P. How to keep the brain awake? The complex molecular pharmacogenetics of wake promotion. Neuropsychopharmacology 2009;34:1625-40.
17. Gordon R, Bernard P, Pack E, Lee K, Choi YM. Pharmacological profile of YKP10A: a novel antidepressant [abstract]. Soc Neurosci 1998;583:24(part 2):Abstract 583.9.
18. Bogan R, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med 2015;16:1102-8.
19. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
20. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-5.
21. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005;28:113-21.
22. Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education, and Welfare publication (ADM 76-338). Rockville, MD: National Institute of Mental Health, 1976.
23. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77.
24. Broughton RJ, Fleming JA, George CF, et al. Randomized, doubleblind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-51.
25. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998;43:88-97.
26. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000;54:1166-75.
27. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22:761-74.
28. Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 2003;26:252-7.
29. Johns M, Hocking B. Daytime sleepiness and sleep habits of Australian workers. Sleep 1997;20:844-9.
30. Nishino S, Okura M, Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 2000;4:57-99 .
31. Amsterdam JD, Brunswick DJ, Hundert M. A single-site, doubleblind, placebo-controlled, dose-ranging study of YKP10A - a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1333-8.
32. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol 2013;23:534-41.
33. Nuvigil (armodafinil) prescribing information. Frazer, PA: Teva Pharmaceuticals, 2015. Available at www.nuvigil.com.